Mark Pegram Selected Research

Mark Pegram Research Topics

Disease

37	Breast Neoplasms (Breast Cancer) 10/2021 - 01/2002
22	Neoplasms (Cancer) 10/2021 - 01/2002
6	Disease Progression 10/2021 - 11/2009
4	Triple Negative Breast Neoplasms 10/2021 - 02/2011
4	Neoplasm Metastasis (Metastasis) 01/2021 - 08/2006
4	Diarrhea 01/2020 - 11/2009
3	Brain Neoplasms (Brain Tumor) 01/2021 - 08/2006
3	Carcinoma (Carcinomatosis) 11/2002 - 01/2002
2	Nausea 01/2020 - 11/2012
2	Vomiting 01/2020 - 11/2012
2	Thrombocytopenia (Thrombopenia) 01/2017 - 11/2012
2	Leukemia 11/2010 - 01/2010
2	Cardiotoxicity 01/2010 - 01/2003
2	Exanthema (Rash) 11/2009 - 06/2005
1	Pathologic Complete Response 10/2021
1	Circulating Neoplastic Cells 01/2020
1	Fatigue 01/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 10/2019
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2017
1	Metabolic Brain Diseases (Encephalopathy, Metabolic) 01/2017
1	Sepsis (Septicemia) 01/2017
1	Peripheral Nervous System Diseases (PNS Diseases) 03/2016
1	Hypoxia (Hypoxemia) 03/2010

Drug/Important Bio-Agent (IBA)

16	Trastuzumab (Herceptin)FDA Link 01/2021 - 01/2003
8	Hormones (Hormone)IBA 10/2021 - 01/2003
8	human ERBB2 proteinIBA 10/2021 - 11/2009
6	taxaneIBA 10/2021 - 01/2003
6	Lapatinib (GW572016)FDA Link 01/2020 - 11/2009
5	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2002
5	ErbB Receptors (EGF Receptor)IBA 10/2019 - 06/2005
4	AnthracyclinesIBA 10/2021 - 01/2003
4	Estrogen ReceptorsIBA 10/2021 - 02/2011
4	AntibodiesIBA 01/2021 - 08/2006
4	pertuzumabIBA 01/2021 - 03/2016
4	Epidermal Growth Factor (EGF)IBA 01/2021 - 07/2006
4	Ado-Trastuzumab EmtansineIBA 01/2020 - 11/2012
4	Capecitabine (Xeloda)FDA Link 01/2020 - 11/2010
4	Pharmaceutical PreparationsIBA 07/2016 - 04/2002
4	PlatinumIBA 09/2004 - 07/2002
3	Taxoids (Taxanes)IBA 10/2021 - 11/2010
3	Progesterone Receptors (Progesterone Receptor)IBA 10/2021 - 02/2011
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 04/2002
3	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2017
3	Letrozole (Femara)FDA LinkGeneric 11/2011 - 11/2009
2	Estrogens (Estrogen)FDA Link 01/2021 - 11/2011
2	neratinibIBA 01/2020 - 10/2017
2	Tyrosine Kinase InhibitorsIBA 01/2020 - 11/2009
2	Transaminases (Aminotransferases)IBA 01/2020 - 11/2012
2	Niclosamide FDA Link 07/2016 - 02/2016
2	Paclitaxel (Taxol)FDA LinkGeneric 03/2016 - 07/2002
2	Phosphotransferases (Kinase)IBA 02/2016 - 09/2007
2	Monoclonal AntibodiesIBA 03/2008 - 07/2006
2	EnzymesIBA 01/2003 - 04/2002
2	raltitrexed (D 1694)IBA 04/2002 - 01/2002
2	NB1011IBA 04/2002 - 01/2002
2	Thymidylate SynthaseIBA 04/2002 - 01/2002
1	Radioisotopes (Radionuclides)IBA 01/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021
1	olaparibIBA 01/2021
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020
1	tucatinibIBA 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	Biosimilar PharmaceuticalsIBA 10/2019
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 08/2018
1	abemaciclibIBA 08/2018
1	palbociclibIBA 08/2018
1	ribociclibIBA 08/2018
1	Estrogen Receptor Modulators (Antiestrogen)IBA 08/2018
1	Diphosphonates (Bisphosphonates)IBA 05/2018
1	Biomarkers (Surrogate Marker)IBA 05/2018
1	Circulating Tumor DNAIBA 10/2017
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2017
1	Cisplatin (Platino)FDA LinkGeneric 07/2016
1	OSM-LIF ReceptorsIBA 08/2012
1	Immunoglobulins (Immunoglobulin)IBA 11/2011
1	epitumomabIBA 11/2011
1	AntigensIBA 11/2011
1	Adenosine Triphosphate (ATP)IBA 11/2010
1	ProdrugsIBA 03/2010
1	Cytotoxins (Cytolysins)IBA 03/2010
1	Mechlorethamine (Nitrogen Mustard)FDA Link 03/2010
1	PR-104AIBA 03/2010
1	Aldo-Keto ReductasesIBA 03/2010
1	PR-104IBA 03/2010
1	Aromatase InhibitorsIBA 11/2009
1	Neoplasm Antigens (Tumor Antigens)IBA 09/2007
1	tyrosine receptor (receptor, tyrosine)IBA 09/2007
1	Complementary DNA (cDNA)IBA 08/2006
1	CarcinogensIBA 08/2006
1	Capsules (Microcapsules)IBA 08/2006
1	Insulin-Like Growth Factor Binding Protein 3IBA 07/2006
1	Growth Factor ReceptorsIBA 07/2006
1	Mitogen-Activated Protein Kinase 1 (p42 MAP Kinase)IBA 07/2006

Therapy/Procedure

25	Therapeutics 10/2021 - 11/2002
11	Drug Therapy (Chemotherapy) 10/2021 - 07/2002
3	Adjuvant Chemotherapy 10/2021 - 04/2012
3	Radiotherapy 01/2021 - 07/2002
1	Precision Medicine 01/2020
1	Immunotherapy 01/2020
1	Biological Therapy 04/2014